State Street SPDR S&P Biotech ETF
554 hedge funds and large institutions have $8.96B invested in State Street SPDR S&P Biotech ETF in 2020 Q3 according to their latest regulatory filings, with 91 funds opening new positions, 192 increasing their positions, 156 reducing their positions, and 57 closing their positions.
60% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 57
23% more repeat investments, than reductions
Existing positions increased: 192 | Existing positions reduced: 156
6% more funds holding
Funds holding: 525 → 554 (+29)
1.47% more ownership
Funds ownership: 169.68% → 171.15% (+1.5%)
4% less capital invested
Capital invested by funds: $9.37B → $8.96B (-$411M)
39% less funds holding in top 10
Funds holding in top 10: 18 → 11 (-7)
68% less call options, than puts
Call options by funds: $922M | Put options by funds: $2.85B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$442M |
| 2 |
N
Natixis
Paris,
France
|
+$112M |
| 3 |
SG Americas Securities
New York
|
+$77.6M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$59.1M |
| 5 |
Squarepoint
New York
|
+$28.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$452M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$345M |
| 3 |
DFO
Duquesne Family Office
New York
|
-$123M |
| 4 |
Barclays
London,
United Kingdom
|
-$68.4M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$54.2M |
XBI Hedge Fund Activity: Q3 2020 in Review
554 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q3 2020, worth a combined $8.96B — down 4.4% from $9.37B a quarter earlier.
Buyers outnumbered sellers: 91 funds opened new XBI positions and 57 closed out — a net gain of 34 holders — while 192 added to existing stakes and 156 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $442M. The largest seller was Goldman Sachs, cutting an estimated $452M.
- 554 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q3 2020, up from 525 in Q2 2020.
- Funds reported $8.96B of State Street SPDR S&P Biotech ETF stock for Q3 2020, down 4.4% quarter-over-quarter.
- 91 funds opened new State Street SPDR S&P Biotech ETF positions in Q3 2020 and 57 closed out, a net change of +34 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q3 2020 was Morgan Stanley, an estimated $442M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q3 2020 was Goldman Sachs, an estimated $452M sold.
Based on aggregated 13F filings for Q3 2020.